N@N

Multiple Revenue Streams and Strong Distribution Base Point to YesDTC Holdings' Upside

_{//business-finance.news-articles.net/content/201 .. bution-base-point-to-yesdtc-holdings-upside.html}
^{Published in Business and Finance on Thursday, June 17th 2010 at 10:40 GMT by Market Wire}  

LOS ANGELES, CA--(Marketwire - June 17, 2010) - BioMedReports, the news portal who first covered the story for a community of highly informed investors, has alerted its readers to YesDTC Holdings (OTCBB: [ YESD ]), a fully reporting over the counter company which has been getting more attention on message boards and chat rooms, which has just acquired the exclusive Japanese marketing rights for all products of BioElectronics, a small medical device company. Clearances to market those products in the Japanese market are reportedly close at hand.

Last year, BioElectronics Corp. saw one of the strongest stock price percentage gains. Small-cap investors watched the stock price rise significantly, from fractions of a cent to nearly a dime in hopes that the company's drug-free, anti-inflammatory devices would receive FDA clearance, but despite multiple attempts, that clearance has yet to be granted.

Analyst Peter DePalma believes YesDTC, which has a much friendlier share structure and an experienced leadership team, could turn into one of the most exciting and undervalued small-cap plays in the medical device related area of the market. He also reports that the company has set its sights on acquiring marketing and distribution rights to multiple brands and technologies which are already approved for commercialization.

"In the days ahead, we believe the company will announce more acquisitions and agreements which will affect both top and bottom line revenue growth and we are advising small-cap investors interested in the space to place the company on their watch list," writes DePalma.

According to the special report, the company is one of the best undiscovered medical device plays because it has the potential to align multiple commercial revenue streams while building a strong distribution base for several medical device and healthcare related products.

The complete analysis of the company appears today at BioMedReports.Com

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

[ http://biomedreports.com/fda-calendar/fda-calendar.html ]

About BioMedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies.

For more biomedical sector and investment news go to [ http://BioMedReports.com ]